Chymotrypsin

CHEMBL1201465 Phase 4 Đã phê duyệt Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A proteolytic enzyme derived from bovine or porcine pancreas that breaks down peptide bonds in proteins, used historically in ophthalmic surgery to facilitate cataract extraction by dissolving zonular fibers, and as an anti-inflammatory agent. Its systemic use as an anti-inflammatory is largely historical and not well supported by modern evidence. Current ophthalmic practice has moved to phacoemulsification techniques that do not require chymotrypsin.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A proteolytic enzyme derived from bovine or porcine pancreas that breaks down peptide bonds in proteins, used historically in ophthalmic surgery to facilitate cataract extraction by dissolving zonular fibers, and as an anti-inflammatory agent. Its systemic use as an anti-inflammatory is largely historical and not well supported by modern evidence. Current ophthalmic practice has moved to phacoemulsification techniques that do not require chymotrypsin.

Yes, Chymotrypsin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201465. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.